Eagle Pharmaceuticals Investors Reach $9.5 Million Settlement

The litigation, involving defendants Scott Tarriff and Brian Cahill, centers on securities claims filed by Nicholas Miller. The court-certified class includes individuals and entities who held the company's publicly traded stock during the specified two-year period. A fairness hearing is scheduled for August 19, 2026, at the Martin Luther King Building & U.S. Courthouse in Newark, where Judge Michael A. Hammer will evaluate the adequacy of the settlement and the requested allocation of attorneys' fees.

Investors seeking to participate in the settlement fund must submit a valid claim form by October 16, 2026. Those who wish to opt out of the class or file objections to the proposed terms must submit their requests by July 29, 2026. Detailed instructions, claim forms, and additional documentation are available through the court-appointed claims administrator at www.EaglePharmaSecuritiesSettlement.com. Failure to submit a timely claim form will result in the forfeiture of any payment, though class members will remain legally bound by the court's final judgments.